中國China Patent OfficeCNIPAPatent LawprosecutionUpdates and Changes
2024年2月28日

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 3: The 15-Day Mailing Period is Mostly Going Away

A Closer Look at the New Presumed Receipt Date Calculation

Background

China has finally released the long-awaited Patent Law Implementation Regulations (“Regulations”) and associated "Patent Examination Guidelines" (“Guidelines”, similar to the United States' MPEP) which provide further clarity and details of the new Chinese patent law. Today’s article will focus on changes that impact how patent applications and related deadlines are managed.

Understanding the Shift in Presumed Receipt Dates

Traditionally, the China National Intellectual Property Administration (CNIPA) presumed the receipt of official documents to be 15 days post-issuance, similar to the European Patent Office's 10-day mailing period. Recent modifications (2023) in European procedures raised questions about potential parallels in China's approach, which has now materialized.

Distinguishing Based on Submission Method

The new regulations determine the presumed receipt date of a patent office submission based on the method of submission — paper or electronic. For paper submissions, either through mail or direct delivery, the status quo remains, preserving the 15-day mailing period. However, for electronic submissions, the receipt date for electronically submitted documents is now the date of entry into the e-filing system, abolishing the traditional 15-day buffer. This adaptation aligns CNIPA’s practices with the broader movement towards digitalization led by prominent organizations like the EPO and WIPO.

Impact of Electronic Filing Dominance

With electronic filings constituting over 90% of applications, this change in deadline calculation is expected to have widespread effect. It notably shortens the response window for applicants, a development that has garnered mixed reactions. While the ease and efficiency of electronic filing are undeniable, the reduction in the time to file a response has sparked concern among patent agents and applicants.

Special Circumstances and Proof of Receipt

Just like the European Patent Office, CNIPA has made accommodations for special cases wherein the actual receipt date diverges from the presumed date. In such scenarios under the new Guidelines, the onus is on the parties involved to substantiate the actual date of receipt, not the CNIPA. This approach is distinct from the EPO’s method, where the burden of proof in disputes about receipt dates lies with the EPO itself, as stipulated by Rules 126(2) and 127(2) EPC.

Transitional Provisions and Future Implications

These changes are not retroactive and will apply to future deadlines set within documents issued by the CNIPA from January 20, 2024, onwards. An intriguing implication of this timeline is the difference in deadlines for documents received just a day apart in January 2024. For instance, a First Office Action received on January 19 would have a response deadline of June 3, 2024, while one received on January 20 would have an earlier deadline of May 20, 2024.

EIP Thoughts

Virtually 100% of our cases at the CNIPA are handled electronically, so this change certainly impacts all of our clients and shortens the time for responding to an office action in China.However, in China it’s relatively straightforward to revive cases that were abandoned due to failure to reply to an office action. Even before that, there are extensions available. As such, even though we will miss the 15-day mailing period, we think having a robust digital patent system at the CNIPA is much more useful overall.

Navigating the New Landscape

As the landscape of China's patent law undergoes these significant changes, it is crucial for stakeholders to stay informed and adapt their strategies accordingly. Our team remains committed to providing expert guidance through these evolving regulations, ensuring that your intellectual property interests in China are managed effectively and in compliance with the latest legal framework.

If you would like to have more information on this matter or would like to have our advice, please feel free to contact us at [email protected].

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

About the Authors

Yolanda Wang is a Principal, Chinese Patent Attorney, and Chinese Patent Litigator at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

Jennifer Che, J.D. is Managing Director and a US Patent Attorney at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

其他文章

China Releases Draft Implementation Guidelines for the Drug Administration Law

2022年6月2日
The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]

First ever Invalidation decision on an RNAi Invention patent in China

2023年12月4日
Decision on Examination of Request for Invalidation (No. 58530) In one of China’s Top 10 Patent Re-examination / Invalidation cases of 2022, an invalidation decision on a patent claiming Hepatitis B Virus (HBV) RNAi compositions (No. 58530) by the Patent Re-examination Board (the “Board”) sheds light on the standard for post filing data for rejections […]

Chinese Courts Cares More About Patent Quality Now (A Doctrine of Equivalents Story)

2022年12月13日
There is no doubt that the drafting quality of a patent can be crucial in determining the success (or failure!) of the patent during litigation. However, due to various reasons, patents often fail to use the right drafting strategies that best protect the invention. Too often, inexperienced or unsophisticated patent drafters merely listen to an […]

Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data

2025年4月1日
“Good Faith” is a challenging concept that brings with it the nuances of a particular jurisdiction’s ideas about honesty, moral values, and societal expectations. Most patent laws around the world include good faith requirements – especially in matters involving the legal and the medical profession – and China is no exception. So what’s the standard? […]

我們過去活動

Top crossarrow-right